CG Oncology: AUA 2026: Ph2 Creto + Gem Combo Data are Compelling

Research evidence excerpt

CG Oncology: AUA 2026: Ph2 Creto + Gem Combo Data are Compelling

Update

May 15, 2026 07:21 PM GMT

Morgan Stanley & Co. LLCMCG Oncology | North America Sean Laaman, Ph.D.

Equity Analyst

AUA 2026: Ph2 Creto + Gem Sean.Laaman@morganstanley.comKatherine Sun +1 212 761-4947

Research Associate

Katherine.Sun@morganstanley.com +1 212 761-5968

Combo Data are Compelling Michael H Riad, Ph.D.

Michael.Riad@morganstanley.com +1 212 761-1309

Key Takeaways Morgan K Gryga

First Phase 2 intravesical‑only combo data for cretostimogene + gemcitabine Morgan.Gryga@morganstanley.com +1 212 761-0824

show high HG‑EFS and compelling CR rates (see below).

CG Oncology (CGON.O, CGON US)

Comparable efficacy across concurrent & sequential dosing and BCG‑exposed/ Biotechnology | United States of America

unresponsive patients are supportive of combo potential in our view. Stock Rating Overweight

Industry View Attractive

Price target $93.00

Combination of cretostimogene (creto)+ gemcitabine (gem) numerically exceeds Shr price, close (May 14, 2026) $69.54

Mkt cap, curr (mm) $5,877prior monotherapy benchmarks. The Phase 2 CORE‑008 Cohort CX results

52-Week Range $75.50-23.32

demonstrate encouraging early efficacy in HR NMIBC with HG-EFS of 96.0% at 3mo

and 89.5% at 6mo in the ITT population (median follow‑up 6.6 months, data cut as

of March 13, 2026). No statistically significant differences in HG‑EFS were observed

between concurrent and sequential treatment arms, and efficacy was comparable

across BCG‑exposed (65.6%) and BCG‑unresponsive (34.5%) populations. High CR

rates at any time were observed in the CIS‑containing population with 85.7%

(24/28) in the ITT population and 92.3% (24/26) in the efficacy‑evaluable

population, with responses maintained across concurrent and sequential schedules.